[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]
[india-drug] Glaxo sues some generic rivals
- From: Edrug <e-drug@usa.healthnet.org>
- Date: Sat, 24 Aug 2002 08:48:49 -0400 (EDT)
(Copied from Edrug. Thanks??..SS)
E-drug: Glaxo sues some generic rivals
---------------------------------------
The neverending issue of patent lawsuits. Copied as fair use. KM]
New York Times August 23, 2002
Glaxo Sues Some Generic Rivals
By DOW JONES/AP
URICH, Aug. 22 (Dow Jones/AP) - GlaxoSmithKline, the British
pharmaceutical company, said today that it had filed lawsuits against
several generic drug makers, accusing them of using a stolen strain of
bacteria to make versions of its antibiotic Augmentin.
A Glaxo spokesman, Alan Chandler, said, "Our intent is to stop the use
of Glaxo's stolen trade secrets." He said the lawsuits were filed on
Aug. 9.
Mr. Chandler said Glaxo had filed suit in a state court in Broomfield,
Colo., against Novartis, the Swiss drug maker; Geneva Pharmaceuticals,
a
unit of Novartis; and Biochemie of Germany. Suits against Ranbaxy
Laboratories of India and Teva Pharmaceutical Industries of Israel have
been filed in a county court in Philadelphia County.
He said the company had recently carried out tests on generic versions
of Augmentin and that the results suggested that the crucial ingredient
had been made using a strain of bacteria developed at GlaxoSmithKline.
"The derivation of the particular strain is particular to Glaxo," Mr.
Chandler said. "It hasn't been made available to third parties and is a
trade secret."
The generic makers have 40 days to respond after the filing, and a
ruling is then expected within 12 to 18 months. The company has asked
for damages for lost profit.
A Novartis spokesman, Mark Hill, said the company would fight the suit.
He said, "We're confident that the lawsuit will show that the Novartis
companies have acted in a legally and ethically correct manner."
Teva and Ranbaxy were not immediately available for comment.
GlaxoSmithKline is trying to stave off generic competition to
Augmentin,
which contributed $2.03 billion in global sales last year.
________________________________________________________________________
Want to sell your car? advertise on Yahoo Autos Classifieds. It's Free!!
visit http://in.autos.yahoo.com
The INDIA-DRUG discussion group is a partnership between SATELLIFE
(www.healthnet.org), WHO Essential Drugs and Medicines Policy
(www.who.ch), and the Delhi Society for the Promotion of the
Rational Use of Drugs (DSPRUD) in India.
To send a message to india-drug, write to: india-drug@usa.healthnet.org
To subscribe or unsubscribe, write to: majordomo@usa.healthnet.org
in the body of the message type: subscribe india-drug OR unsubscribe india-drug
To contact a person, send a message to: india-drug-help@usa.healthnet.org
|